LXRX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
692.0K
-96.7%
21.1M
+295.4%
5.3M
-62.4%
14.2M
-50.9%
28.9M
Cost of Revenue
39.0K
-63.9%
108.0K
-46.3%
201.0K
+1910.0%
10.0K
-69.7%
33.0K
Gross Profit
653.0K
-96.9%
21.0M
+308.8%
5.1M
-63.8%
14.2M
-50.8%
28.8M
Operating Expenses
27.2M
+15.3%
23.6M
+17.5%
20.1M
-23.9%
26.4M
+5.0%
25.1M
R&D
17.4M
+36.7%
12.8M
+12.7%
11.3M
-39.7%
18.8M
+19.1%
15.7M
SG&A
9.8M
+5.6%
9.2M
+5.4%
8.8M
+15.2%
7.6M
-18.7%
9.3M
Operating Income
-26540000
-926.3%
-2586000
+82.7%
-14936000
-22.6%
-12187000
-426.2%
3.7M
EBITDA
-26438000
-967.8%
-2476000
+83.3%
-14818000
-23.1%
-12036000
-407.7%
3.9M
Net Income
-31775000
-2946.5%
-1043000
+93.3%
-15530000
-21.6%
-12769000
-492.7%
3.3M
EPS (Basic)
$-0.07
$0.00
+100.0%
$-0.04
+0.0%
$-0.04
-500.0%
$0.01
EPS (Diluted)
$-0.07
$0.00
+100.0%
$-0.04
+0.0%
$-0.04
-500.0%
$0.01
Shares (Diluted)
437.7M
+9.3%
400.2M
+10.2%
363.2M
-0.1%
363.4M
-0.0%
363.6M
Lexicon Pharmaceuticals (LXRX) โ€” Financials